Research Paper Volume 12, Issue 23 pp 23795—23807

Figure 7. In vivo anti-tumor activity of DMC-BH in the PDTX tumor model. (A) A scheme illustrating the process of creating the patient-derived tumor model. (B) Tumor growth curves of mice after treatment with 7.5 mg/kg, 15 mg/kg or 30 mg/kg DMC-BH or 20 mg/kg TMZ. (C) Average tumor weight at day 21 after different treatments. (D) Quantification of the Ki67-positive area in different treatment groups. (E) Representative H&E-stained tumor slices and Ki67 immunofluorescence labeled tumor tissue sections from different treatments groups. The data are shown as mean ± SD (n = 6).